FDA again rejects Vanda’s Hetlioz for jet lag after yearslong dispute and ‘long‑shot’ re‑review on January 13, 2026 decision letter Hetlioz jet lag disorder NDA phase advance protocol rejection Supplement tasimelteon United States Food and Drug Administration Vanda Pharmaceuticals +
FDA again rejects Vanda’s Hetlioz for jet lag after yearslong dispute and ‘long‑shot’ re‑review on January 12, 2026 decision letter Hetlioz jet lag disorder NDA phase advance protocol rejection Supplement tasimelteon United States Food and Drug Administration Vanda Pharmaceuticals +
FDA again rejects Vanda’s Hetlioz for jet lag after yearslong dispute and ‘long‑shot’ re‑review on January 12, 2026 decision letter Hetlioz jet lag disorder NDA phase advance protocol rejection Supplement tasimelteon United States Food and Drug Administration Vanda Pharmaceuticals +
FDA again rejects Vanda’s Hetlioz for jet lag after yearslong dispute and ‘long‑shot’ re‑review on January 09, 2026 decision letter Hetlioz jet lag disorder NDA phase advance protocol rejection Supplement tasimelteon United States Food and Drug Administration Vanda Pharmaceuticals +
FDA again rejects Vanda’s Hetlioz for jet lag after yearslong dispute and ‘long‑shot’ re‑review on January 09, 2026 decision letter Hetlioz jet lag disorder NDA phase advance protocol rejection Supplement tasimelteon United States Food and Drug Administration Vanda Pharmaceuticals +
Vanda Ends Lawsuits Against FDA in Broad Settlement, Paving Way for Drug Review Progress on October 02, 2025 Clinical Trials collaborative framework Drug Approval Employment Termination Hetlioz jet lag disorder lawsuit Motion Sickness sNDA Tradipitant United States Food and Drug Administration Vanda Pharmaceuticals +
Federal Appeals Court Overturns FDA Rejection of Vanda’s Hetlioz for Jet Lag Disorder on August 19, 2025 Clinical Trials Evidence Federal Appeals Court Hetlioz jet lag disorder New Drug Application regulatory law sNDA United States Food and Drug Administration Vanda Pharmaceuticals +